Cracking Open the IPO Window for Pre-Commercial Device Companies

DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.

One can only shake one's head in admiration. In December 2004, Warburg Pincus bought two-thirds, or $14.5 million worth, of DexCom Inc. 's $22.5 million Series D round, paying an as-converted price of $5.38 per share [See Deal]. Barely five months later, the glucose monitoring company went public, raising $50 million at $12 a share [200530066]. Since the April 13th offering, shares have lost a bit—but in a generally dismal market, they're holding their own. Granted the shares continue to do so for the 180-day lock-up period, Warburg will have more than doubled its money in about a year.

A nice, but not terribly unusual story of VC timing? Perhaps. But DexCom had been struggling to raise capital before...

More from Strategy

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

More from Business

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.